Identification of acute HIV infection (AHI) has direct implications for the safety of blood products, HIV prevention, due to patient high infectiousness and HIV treatment. Antiretroviral therapy at this stage allows for potential immunological and viral advantages and latent reservoirs reduction [1] . Recently published CDC recommendations for HIV testing suggest that 4th generation (4thG) immunoassays (IAs) for the combined detection of HIV p24-antigen and HIV-antibody should become the standard of care for HIV testing because they are more sensitive than 3rd generation assays [2, 3] . The same guidelines suggest that confirmation of HIV screening reactivity should be assessed by the detection of viral genome (HIV-RNA) instead with western blot (WB) due to the significant less sensitivity of WB in the early stages of HIV infection. In contrast to other 4thG IAs, a recently CE approved HIV assay, the LIAISON-XL Murex HIV Ab/Ag (DiaSorin, Saluggia, Italy) offers the advantage of a signal discrimination between HIV-p24 and HIV-antibody reactivity.
In [5] were identified in 5/5 and 3/3 patients (HIV-RNA >500,000 and >300,000 copies/mL, respectively). WB was negative in Fiebig stages II and III patients (n = 8) and indeterminate in Fiebig stage IV (7 patients) ( Table 1 ). p24 correlation with HIV-RNA was good (r = 0.822, p = 0.0002, 95% CI 0.535-0.939).
In conclusion, 4thG IAs are very sensitive for the detection of AHI and they enhance the early detection of HIV infection during the acute phase, when substantial HIV transmission occurs, thus representing an important advance in HIV testing to address HIV public health burden. Confirmation of their results should not include WB, but the detection of HIV-RNA due to the lack of WB sensitivity in the early stages of HIV infection. Recently, commercialized 4thG IAs allowing signal discrimination between reactivity due to p24 and HIV antibody offer the advantage of a better classification of AHI. This is certainly an added value in situations where HIV-RNA testing is not available.
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